Penny Stocks Showing Signs of Breaking Out: ENZC, NBRI, XTPT, SDRC
Penny Stocks Showing Signs of Breaking Out: ENZC, NBRI, XTPT, SDRC
The dream of buying into a company for only a few cents is the drive behind many investors venturing into the penny stocks investment world. The prospect of generating gains of over 100% in a single day or hours only strengthens the resolve to hold thousands of shares for a relatively small amount of invested capital.
Nevertheless, penny stocks are a double-edged sword. While it is possible to generate significant returns, it is equally likely to lose everything on things going south. Small-cap companies’ lack of liquidity and large bid-ask spreads call for extreme caution when selecting penny stocks.
Therefore, stock screening is essential while looking to venture into the world of penny stocks. It is the only way to filter to trade stocks that align with a particular strategy and risk tolerance. Screening also makes it easy to narrow down to small-cap companies with an edge in their respective fields and expected to be winners in the long run. This article focuses on sub-penny stocks worth watching this month, Including ENZC NBRI XTPT, and SDRC.
Enzolytics Making Strides on HIV/AID Treatment
Enzolytics, Inc. (OTC: ENZC) is a small-cap company for investors eyeing exposure in the drug development business, focusing on commercializing proprietary proteins for treating debilitating infectious diseases. Its edge in the segment stems from its patented anti-HIV therapeutics and methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases.
ITV1 Immune Therapeutic Vaccine is ENZC’s proprietary treatment proving effective in treating HIV/AIDS. Patented in the US, the vaccine has also shown tremendous potential in modulating the immune system.
The final protocol for administering the immune therapeutic vaccine in Rwanda under the supervision of Neuro Pharma Ltd under a fast-track protocol has been completed. The impact of the treatment on the HIV/AIDS virus is to be reported after a 17-week cycle.
Harry Zhabiov, CSO of VIRO stated, ” As we count down the days to the initial injections in victims of HIV/Aids in African patients we feel confident that all the hard work and support we have received over the 15 year journey will soon be rewarded”.
Once the initial patients are treated, and the vaccine proves effective, Enzolytics intends to provide additional treatments targeting up to 30,000 patients in central and east Africa. The biotechnology firm has received a response from the European Medicines Agency, signaling that the pharmacokinetics study will follow ELAZA standards.
In addition, its proprietary technology for developing human monoclonal antibodies is being used to produce antibody therapeutics for treating coronavirus, HIV1, and the Feline Leukemia virus. It has also analyzed epitopes of animal viruses from which it plans to develop mAbs for treating the viruses.
Additionally, Enzolytics has made substantial strides in the proposed business combination of its operating subsidiaries Biogenysis and Virogenetics with Sagaliam Acquisition Corp. The merger should make it easy to align the talents to focus on successfully advancing the various novel treatments in the pipeline.
The $250 million merger is expected to provide the much-needed finances to accelerate the development and expansion of existing and future technology platforms. Sagaliam intends to raise additional capital to fund the clinical trials of ITV1.
Consequently, Enzolytics stands to transform into a global biotechnology company leveraging artificial intelligence to enhance treatment developments. Collaboration with Samsung Biologics is expected to strengthen the development of the various human monoclonal antibodies leading to the production of multiple Monoclonal antibodies.
ENZC intends to expand its artificial intelligence division to enhance the drug discovery and development business. The expansion should position the company as a market leader when large pharmaceutical companies are increasingly looking to partner with small companies on the use of AI to enhance their portfolios and pipelines.
North Bay Resources Turns to Carbon-Negative Cementless Concrete For Value Generation
North Bay Resources Inc. (OTC: NBRI) is a junior mining company that has set out to build a portfolio of viable mining prospects worldwide. It currently owns a multitude of significant mining properties, including an advanced-stage Mount Washington Project on Vancouver Island and the Tulameen Platinum Project. Its portfolio includes strategic mineral resources, including Vanadium Crystalline and Rare Earth Metals.
Recently, NBRI has entered into a memorandum of understanding with CarbonMeta Technologies Inc (OTC: COWI) to create a joint venture. CarbonMeta Green Resources Canada is the new joint venture that will expand North Bay Resources into producing carbon-negative cementless concrete using Olivine.
The subsidiary will be a research and development center that produces carbon-negative cementless concrete while operating a production facility. The subsidiary is to leverage the Olivine produced at North Bay’s Tulameen project, believed to have 15 million tons of Olivine.
The new joint venture should strengthen North Bay Resources’ efforts to reduce carbon emissions that are highly needed to impact the environment positively. In the long run, the joint venture should create a sustainable and profitable business that benefits the company and shareholders.
NBRI also intends to pursue the extraction of magnesium and platinum group of metals for its mining operations and take advantage of the growing demand for the metals for industrial purposes. It also plans to partner with CarbonMeta to develop a microwave-assisted technology for enhancing the extraction and magnesium and platinum.
Xtra Energy Corporation Partners Sidney Resource to Unlock Antimony Value
Xtra Energy Corporation (OTC: XTPT) is a rare earth metal company focused on antimony exploration in its flagship project in Nevada. The penny stock has been making waves on the small-cap company inking a non-disclosure agreement with Sidney Resources Corporation, a subsidiary of the Irish metals.
The NDA lays the groundwork for the collaboration between Xtra Energy Corporation and Irish Metals. The two are to join forces on ore refinement and processing techniques. The ultimate goal is to develop an antimony processing plant in Nevada.
Irish metals are a perfect partner that should allow Xtra Energy Corporation to achieve its goals as it already enhances antimony processing with near zero emissions and improved economics. By joining forces, the two hoped to establish the USA as an independent antimony-producing nation, not dependent on foreign supplies.
Sidney’s resources are to help Xtra Energy produce antimony with a plant and operations that reduce environmental impact while producing antimony cost-effectively to optimize value generation.
Sidney Resources Focused on Clean Technology
Sidney Resources (OTC: SDRC) is a penny stock offering exposure to acquiring, exploring, and producing gold and silver properties. It is interested in the Lucky Ben Mine Group in the Warren Mining District in Idaho, best known for gold production.
In addition, Sidney Resources bills itself as a clean technology, clean refining, clean water, and extraction company that seeks to change the way the world develops. Its primary goal is to provide a cleaner world so children can experience their brilliance. By developing technologies and implementing cleaner methodologies, it hopes to maintain a sustainable future and generate significant shareholder value.
Additionally, it has entered into a joint venture with Xtra Energy to develop a flagship American Antimony project. The ultimate goal is to enhance antimony production in Nevada in an environmentally friendly and cost-effective way.
